Campbells acted as Cayman Islands and British Virgin Islands counsel to Aptorum Group Limited (“Aptorum”) on the proposed US$250 million reverse merger with YOOV Group Holding Ltd (“YOOV”); and the simultaneous spin-off of APM’s existing business.
The proposed merger transaction involves, among others, a wholly-owned subsidiary of Aptorum incorporated under the laws of the British Virgin Islands (“Merger Sub”) merges with and into YOOV; and the merger is considered a “reverse merger” since the shareholders of YOOV will control and own a majority stake of Aptorum following the merger. As such, the merger is subject to NASDAQ’s approval of the combined company’s initial listing application.
Aptorum is a Nasdaq-listed clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases.
YOOV is a business artificial intelligence (AI) and automation platform that goes beyond traditional automation by applying advanced AI techniques to optimize various aspects of business operations.
The Campbells team was led by Jenny Nip, our Partner and Head of China Practice in our Hong Kong office with the support from our legal manager Chantelle Chan.
